1. ALLA AKTIER
  2. NYHETER
  3. CANTARGIA

Cantargia

Nyheter Cantargia Nyheter alla bolag

Cantargia to participate at Leerink Partners Global Healthcare Conference

Cantargia AB (publ) (“Cantargia”) (Nasdaq Stockholm: CANTA) today announced that members of Cantargias management will participate in one-on-one meetings at the Leerink Partners Global Healthcare Conference in Miami, Florida on Wednesday, March 11, 2026.

For further information, please contact
Hilde Steineger, CEO
Telephone: +46 (0)46-275 62 60
E-mail: info@cantargia.com

About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. Cantargia’s oncology program, the antibody nadunolimab (CAN04), is being studied clinically, primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia’s second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases. In September 2025, the acquisition of CAN10 by Otsuka Pharmaceutical was completed.
 
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.

Attachments
Cantargia to participate at Leerink Partners Global Healthcare Conference

Datum 2026-01-28, kl 10:00
Källa MFN
Bifogade filer
Cantargia to participate at Leerink Partners Global Healthcare Conference
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!